ANL 28.18 Decreased By ▼ -0.12 (-0.42%)
ASC 17.40 Increased By ▲ 0.70 (4.19%)
ASL 23.90 Increased By ▲ 0.35 (1.49%)
AVN 91.66 Decreased By ▼ -0.27 (-0.29%)
BOP 9.65 Decreased By ▼ -0.13 (-1.33%)
BYCO 9.70 Increased By ▲ 0.02 (0.21%)
DGKC 111.25 Decreased By ▼ -0.35 (-0.31%)
EPCL 48.05 Decreased By ▼ -0.25 (-0.52%)
FCCL 21.42 Decreased By ▼ -0.43 (-1.97%)
FFBL 28.12 Increased By ▲ 0.73 (2.66%)
FFL 19.09 Increased By ▲ 0.57 (3.08%)
HASCOL 14.57 Decreased By ▼ -0.13 (-0.88%)
HUBC 84.40 Decreased By ▼ -0.40 (-0.47%)
HUMNL 7.18 Decreased By ▼ -0.09 (-1.24%)
JSCL 31.18 Increased By ▲ 0.38 (1.23%)
KAPCO 40.03 Decreased By ▼ -0.53 (-1.31%)
KEL 4.07 Decreased By ▼ -0.06 (-1.45%)
LOTCHEM 16.00 Increased By ▲ 0.35 (2.24%)
MLCF 42.81 Decreased By ▼ -0.25 (-0.58%)
PAEL 39.49 Increased By ▲ 0.06 (0.15%)
PIBTL 12.80 Decreased By ▼ -0.05 (-0.39%)
POWER 11.20 Decreased By ▼ -0.21 (-1.84%)
PPL 95.30 Decreased By ▼ -0.69 (-0.72%)
PRL 24.18 Decreased By ▼ -0.22 (-0.9%)
PTC 9.65 Decreased By ▼ -0.05 (-0.52%)
SILK 1.20 Decreased By ▼ -0.01 (-0.83%)
SNGP 45.46 Decreased By ▼ -0.40 (-0.87%)
TRG 106.90 Increased By ▲ 4.02 (3.91%)
UNITY 32.11 Increased By ▲ 0.71 (2.26%)
WTL 1.17 Decreased By ▼ -0.03 (-2.5%)
BR100 4,846 Increased By ▲ 9.99 (0.21%)
BR30 24,561 Increased By ▲ 115.85 (0.47%)
KSE100 45,792 Increased By ▲ 65.78 (0.14%)
KSE30 19,049 Increased By ▲ 29.37 (0.15%)
Business & Finance

Pfizer says analysis shows 3.8pc of participants experienced fatigue

  • It said the updated analysis was based on 8,000 trial participants.
  • Pfizer also added that there was a second adverse event with a frequency of at least 2% in the trial.
18 Nov 2020

NEW YORK: Pfizer Inc on Tuesday updated its analysis of the safety profile of its COVID-19 vaccine seen during its large, late-stage trial, saying that 3.8% of participants experienced fatigue after receiving a second dose of the shot.

It said the updated analysis was based on 8,000 trial participants. Pfizer said in a previous analysis that 3.7% of 6,000 volunteers had experienced fatigue.

Pfizer also added that there was a second adverse event with a frequency of at least 2% in the trial. The US drugmaker said 2% of participants experienced headaches after the second shot.